Ranbaxy Laboratories was established in 1961. It is a research-based international pharmaceutical company serving customers in over 150 countries and has experience of more than 50 years in providing high quality, affordable medicines trusted by healthcare professionals and patients.
Ranbaxy is a member of the Daiichi Sankyo Group which is a leading global pharma innovator, headquartered in Tokyo, Japan.
Ranbaxy has operations in 43 countries and 21 manufacturing facilities spread across eight countries. The company covers all the top 25 pharmaceutical markets of the world and has a robust presence across both developed and emerging markets. Driven by innovation and through their continued focus on research & development (R&D), Ranbaxy has achieved several regulatory approvals in both developed and emerging markets.
Ranbaxy Laboratories: Quality and Patients first
|2012||Launches India's first New Chemical Entity (NCE), Synriam|
|2011||Becomes the first Indian pharmaceutical company to cross global revenues of US$ 2 billion|
|2010||Launches First-to-File (FTF) product Donepezil hydrochloride tablets; enters golden jubilee year|
|2008||Redefines business model by bringing in Daiichi Sankyo Co Ltd as a majority partner|
|2007||Signs a new R&D agreement with GSK and expands drug development responsibilities|
|2006||Acquires the unbranded generic business of GSK in Italy and Spain|